Clinical Trial Finder

Many patients with cardiomyopathy are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Inflammatory/Familial Dilated Cardiomyopathy: Is There a Link to Autoimmune Diseases? TP9a

Condition:   Non Ischemic Cardiomyopathy
Sponsors:   Philipps University Marburg Medical Center;   Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK);   Competence Network Heart Failure
Active, not recruiting - verified March 2017

Genomic Sequencing in Patients With HCM Undergoing Septal Myectomy

Conditions:   Hypertrophic Cardiomyopathy;   Genetic Disease;   Gene Product Sequence Variation
Intervention:   Genetic: Genomic sequencing
Sponsor:   The Cleveland Clinic
Not yet recruiting - verified March 2017

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Condition:   Heart Failure
Interventions:   Drug: Empagliflozin;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Not yet recruiting - verified March 2017

The PARTNER 3 - AVIV Trial

Conditions:   Aortic Stenosis;   Cardiomyopathy, Hypertrophic
Intervention:   Device: Edwards SAPIEN 3 transcatheter valve, Model 9600TFX
Sponsor:   Edwards Lifesciences
Recruiting - verified March 2017

Pulse Reduction On Beta-blocker and Ivabradine Therapy

Conditions:   Dilated Cardiomyopathies, Idiopathic;   Heart Failure, Systolic;   Ventricular Remodeling;   Electrical Remodeling
Interventions:   Drug: Ivabradine;   Drug: Placebo
Sponsors:   University of Colorado, Denver;   American Heart Association;   University of Utah
Recruiting - verified March 2017

MOMENTUM 3 Continued Access Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Intervention:   Device: HeartMate 3 LVAS
Sponsors:   St. Jude Medical;   Thoratec, LLC
Recruiting - verified March 2017

Quantitative Cardiac Parametric Mapping (Myomapping)

Condition:   Cardiomyopathy, Myocarditis, Ischemic Heart Disease
Intervention:   Other: Cardiac Magnetic Resonance (CMR) imaging techniques
Sponsor:   Medical University of South Carolina
Recruiting - verified March 2017

Predischarge Initiation of Ivabradine in the Management of Heart Failure (PRIME-HF)

Condition:   Heart Failure
Interventions:   Drug: ivabradine;   Other: Usual Care
Sponsors:   Duke University;   Amgen
Recruiting - verified November 2016

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

Condition:   Amyloidosis
Interventions:   Drug: GSK2315698 (CPHPC);   Biological: GSK2398852 (anti-SAP mAb)
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified March 2017

Carpal Tunnel Syndrome and Amyloid Cardiomyopathy

Conditions:   Amyloidosis;   Cardiomyopathy;   Transthyretin Amyloidosis;   Senile Systemic Amyloidosis;   Carpal Tunnel Syndrome
Sponsor:   The Cleveland Clinic
Recruiting - verified April 2016

Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life

Condition:   Acute on Chronic Systolic Congestive Heart Failure
Interventions:   Procedure: Reversible Pulmonary Artery Banding;   Device: GORE-TEX DualMesh EMERGE PLUS Biomaterial
Sponsor:   Loma Linda University
Recruiting - verified March 2017

Global Non-interventional Heart Failure Disease Registry

Condition:   Acute Heart Failure
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2017

Allogeneic Stem Cell Therapy in Heart Failure

Condition:   Heart Failure
Interventions:   Biological: Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC);   Biological: Placebo
Sponsor:   JKastrup
Recruiting - verified March 2017

Intravenous Administration of Allogeneic Bone Marrow Derived Multipotent Mesenchymal Stromal Cells (MSCs) in Patients With Recent Onset Anthracycline-Associated Cardiomyopathy

Condition:   Cardiomyopathy
Interventions:   Biological: Human Mesenchymal Stem Cells (hMSCs);   Other: Standard of Care
Sponsors:   M.D. Anderson Cancer Center;   Texas Medical Center (TMC)
Recruiting - verified March 2017

Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome

Conditions:   Brugada Syndrome;   Arrhythmogenic Right Ventricular Cardiomyopathy
Intervention:   Drug: flecainide iv
Sponsor:   New York University School of Medicine
Recruiting - verified March 2017

Dabrafenib and Trametinib in People With BRAF V600E Mutation Positive Lesions in Erdheim Chester Disease

Condition:   BRAF V600E Mutation
Interventions:   Drug: Dabrafenib Mesylate;   Drug: Trametinib Dimethyl Sulfoxide
Sponsor:   National Human Genome Research Institute (NHGRI)
Suspended - verified March 21, 2017

MOMENTUM 3 IDE Clinical Study Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Interventions:   Device: HeartMate 3 LVAS;   Device: HeartMate II LVAS
Sponsors:   Thoratec Corporation;   St. Jude Medical
Active, not recruiting - verified March 2017

Quantitative Detection of Circulating Donor-Specific DNA in Organ Transplant Recipients (DTRT-Multi-Center Study)

Conditions:   Cardiovascular Disease;   Acute Rejection of Cardiac Transplant;   Cardiac Transplant Rejection;   Heart Transplant Failure and Rejection
Intervention:   Diagnostic Test: Blood Draw of up to 10 ml
Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Columbia University;   Duke University;   University of Arkansas;   Emory University;   Children's Healthcare of Atlanta;   Vanderbilt University;   TAI Diagnostics, Inc.
Recruiting - verified March 2017

Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor Mutations

Conditions:   Type 2 Diabetes Mellitus;   Prediabetes (Insulin Resistance, Impaired Glucose Tolerance);   Familiar Hypocalcuric Hypercalcemia;   Healthy Volunteers;   Type 1 Diabetes Mellitus
Interventions:   Device: 1H/ 13C and 31P Magnetic Resonance Spectroscopy;   Other: Meal Tolerance Test;   Other: Hyperglycemic-hyperinsulinemic clamp
Sponsor:   Medical University of Vienna
Recruiting - verified March 2017

Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

Condition:   Aortic Valve Stenosis
Interventions:   Device: Portico transcatheter aortic valve;   Device: Commercially available transcatheter aortic valve
Sponsor:   St. Jude Medical
Recruiting - verified March 2017

Patient and Physician Survey Determinants of Appropriate ICD Utilization

Condition:   Heart Failure, Systolic
Sponsors:   Todd M Koelling, MD;   Medtronic
Completed - verified March 2017

Ranolazine Implantable Cardioverter-Defibrillator Trial

Conditions:   Ischemic Cardiomyopathy;   Nonischemic Cardiomyopathy;   Heart Failure
Intervention:   Drug: Ranolazine
Sponsor:   University of Rochester
Completed - verified March 2017

Long-term Evaluation of Patients Receiving Bone Marrow-derived Cell Administration for Heart Disease

Conditions:   Acute Myocardial Infarction;   Ischemic Cardiomyopathy;   Dilated Cardiomyopathy;   Heart Failure
Intervention:   Biological: autologous bone marrow-derived cells
Sponsor:   Johann Wolfgang Goethe University Hospital
Active, not recruiting - verified March 2017

Transthyretin-Associated Amyloidoses Outcome Survey (THAOS)

Conditions:   Transthyretin Mutations;   Transthyretin Amyloidosis
Intervention:   Other: None. Observational Study.
Sponsor:   Pfizer
Recruiting - verified March 2017

Cardiac Stem Cell Infusion in Patients With Ischemic CardiOmyopathy (SCIPIO)

Conditions:   Coronary Artery Disease;   Congestive Heart Failure
Intervention:   Biological: Treatment group
Sponsors:   University of Louisville;   Brigham and Women's Hospital;   Jewish Hospital and St. Mary's Healthcare
Completed - verified March 2017

Clinical and Basic Investigations Into Hermansky-Pudlak Syndrome

Conditions:   Albinism;   Intestinal Disease;   Kidney Disease;   Myocardial Disease;   Pulmonary Fibrosis
Sponsor:   National Human Genome Research Institute (NHGRI)
Recruiting - verified March 9, 2017